antinucleotide
microantibody
zanolimumab
alacizumab
heterophile
immunoaffinity
oportuzumab monatox
immunogen
conatumumab
immunoproteomics
-toxa-
polyvalent
affitin
toripalimab
zenocutuzumab
paratope
retifanlimab
guselkumab
countercorrelated
dinutuximab
solitomab
ziltivekimab
antisynthetase
antigenomic
immunoadaptor
vanucizumab
sintilimab
sasanlimab
pozelimab
phosphospecific
heterophilic
robatumumab
duligotuzumab
radioimmunoelectrophoresis
bursopentine
immunoaccessible
inotuzumab
oleclumab
immunocytology
immunoprotein
-ab
intetumumab
properdin
siltuximab
glembatumumab
patritumab
immunoblotting
affibody
immunodepleted